Last reviewed · How we verify
lumefantrine-artemether and efavirenz
At a glance
| Generic name | lumefantrine-artemether and efavirenz |
|---|---|
| Also known as | Coartem, Sustiva |
| Sponsor | Makerere University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extended Duration Artemether-lumefantrine Treatment for Malaria in Children (PHASE4)
- Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals (PHASE4)
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations (PHASE1)
- Drug Interaction Study Between Antimalarial and Anti-HIV Medications (PHASE1)
- Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lumefantrine-artemether and efavirenz CI brief — competitive landscape report
- lumefantrine-artemether and efavirenz updates RSS · CI watch RSS
- Makerere University portfolio CI